CD8A and neoplasm: Combined ICAM-1-targeted ADCs with B7-H3 × CD3 BsAbs is another innovated approach, which both enhances tumor cell killing and remodels the TIME through activation of dendritic cells, promoting CD8+ T-cell infiltration and reducing immunosuppressive cell populations such as MDSCs and Tregs [232].